the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Head and Neck Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB16-0680 Vokes, Everett An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Checkmate 651) Details
Phase II
Study No PI Title
IRB16-1718 Seiwert, Tanguy Phase Ib/II trial of IPH2201 (Monalizumab) And Cetuximab in patients with HPV (+) and HPV (-) recurrent or metastatic squamous cell carcinoma of the head and neck Details
IRB16-1678 Vokes, Everett A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Details
IRB17-0104 Seiwert, Tanguy A Phase II Trial of Nivolumab/Nab-Paclitaxel/Carboplatin Induction Chemotherapy followed by Response-Stratified Locoregional Therapy for Patients with Locoregionally Advanced HPV-Related Oropharyngeal Cancer – the OPTIMA II Trial Details
IRB15-1632 Seiwert, Tanguy A randomized, double-blind Phase II study of adjuvant pembrolizumab versus placebo in head and neck cancers at high risk for recurrence Details
CIRB15-1357 Sharma, Manish EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB15-0835 Luke, Jason A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma Details
Phase I
Study No PI Title
IRB16-1718 Seiwert, Tanguy Phase Ib/II trial of IPH2201 (Monalizumab) And Cetuximab in patients with HPV (+) and HPV (-) recurrent or metastatic squamous cell carcinoma of the head and neck Details
IRB15-1617 Seiwert, Tanguy 1. A Phase 1B/3 Multicenter, Randomized, Open-label Trial of Talimogene Laherparepvec in combination with Pembrolizumab for the Treatment of Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck -MASTERKEY 232 Details
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies Details
IRB16-0538 Luke, Jason A Multi-Center, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies Whose Disease has Progressed on PD-1 or PD-L1 Immune Checkpoint Inhibitors Details
IRB16-0263 Luke, Jason A Phase I, Open-Label, Dose Escalation Study of MGA271 in Combination with Ipilimumab in Patients with B7-H3-expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-small Cell Lung Cancer, and Other B7-H3-Expressing Cancers Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1807 Luke, Jason A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas Details
IRB15-1767 Luke, Jason A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers Details
IRB15-1024 Luke, Jason A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors Details
IRB15-0835 Luke, Jason A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma Details
IRB13-0936 Gajewski, Thomas A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors Details
12-1554 Seiwert, Tanguy Nab-Paclitaxel-based re-induction chemotherapy followed by response-stratified chemoradiotherapy in patients with previously treated squamous cell carcinoma of the head and neck. Details
12-1667 Gajewski, Thomas A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Details
Others
Study No PI Title
11-0265 De Souza, Jonas Randomized Placebo- Controlled Phase II Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesion of the Head and Neck Details
15410A Seiwert, Tanguy Utilization of Previously Banked Tissues from Patients with Head and Neck and Lung Cancer for Analysis of DNA repair markers and Correlation With Clinical Data
8980 Blair, Elizabeth Tissue Procurement and Laboratory Core


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .